{
    "clinical_study": {
        "@rank": "3397", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients\n      who have metastatic skin or eye melanoma."
        }, 
        "brief_title": "Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma", 
        "completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Intraocular Melanoma", 
            "Melanoma (Skin)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Uveal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Assess the antitumor activity of pyrazoloacridine (PZA) in chemotherapy naive patients\n           with metastatic cutaneous or ocular melanoma.\n\n        -  Determine the toxic effects of PZA in this patient population.\n\n        -  Determine the pharmacokinetic profile of PZA in these patients.\n\n      OUTLINE: Patients are stratified into cutaneous or ocular melanoma treatment groups.\n\n      Patients receive pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 21\n      days in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: Approximately 28-70 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed metastatic cutaneous or ocular melanoma that is chemotherapy\n             naive\n\n          -  Bidimensionally measurable disease\n\n          -  No pleural effusions or ascites\n\n          -  No untreated CNS metastases\n\n          -  Stable brain metastases by CT or MRI scan\n\n               -  At least 4 weeks since prior steroid therapy\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  WBC at least 4,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN)\n\n          -  Alkaline phosphatase no greater than 2.5 times ULN (unless due to hepatic metastases)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No active infection\n\n          -  No known hypersensitivity to E.coli derived proteins\n\n          -  No other serious medical problems\n\n          -  No more than 1 primary malignancy within past 5 years, other than:\n\n               -  Nonmelanomatous skin cancer\n\n               -  Carcinoma in situ of the cervix\n\n          -  No history of spinal cord compression\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Prior biologic therapy allowed (e.g., interleukin-2, interferon alfa, or vaccine\n             therapy)\n\n        Chemotherapy:\n\n          -  No prior chemotherapy\n\n        Endocrine therapy:\n\n          -  See Disease Characteristics\n\n        Radiotherapy:\n\n          -  Prior radiotherapy for primary ocular melanoma, brain metastases, or to metastatic\n             sites encompassing less than 25% of the bone marrow allowed\n\n          -  No other prior radiotherapy\n\n        Surgery:\n\n          -  At least 2 weeks since prior surgery and recovered"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003802", 
            "org_study_id": "JHOC-J9875, CDR0000066946", 
            "secondary_id": [
                "U01CA063437", 
                "P30CA006973", 
                "JHOC-98111005", 
                "JHOC-JH9875", 
                "JHOC-T96-0116", 
                "NCI-T96-0116"
            ]
        }, 
        "intervention": {
            "intervention_name": "pyrazoloacridine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "NSC 366140"
        }, 
        "keyword": [
            "iris melanoma", 
            "ciliary body and choroid melanoma, small size", 
            "ciliary body and choroid melanoma, medium/large size", 
            "extraocular extension melanoma", 
            "recurrent intraocular melanoma", 
            "stage IV melanoma", 
            "recurrent melanoma"
        ], 
        "lastchanged_date": "December 12, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/JHOC-98111005"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21231-2410"
                }, 
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma", 
        "overall_official": {
            "affiliation": "Sidney Kimmel Comprehensive Cancer Center", 
            "last_name": "William H. Sharfman, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003802"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }, 
    "geocoordinates": {
        "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins": "39.29 -76.612"
    }
}